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ABSTRACT
Background 70%–84% of individuals with antipsychotic 
treatment resistance show non- response from the first 
episode. Emerging cross- sectional evidence comparing 
cognitive profiles in treatment resistant schizophrenia to 
treatment- responsive schizophrenia has indicated that 
verbal memory and language functions may be more 
impaired in treatment resistance. We sought to confirm 
this finding by comparing cognitive performance between 
antipsychotic non- responders (NR) and responders (R) 
using a brief cognitive battery for schizophrenia, with a 
primary focus on verbal tasks compared against other 
measures of cognition.
Design Cross- sectional.
Setting This cross- sectional study recruited antipsychotic 
treatment R and antipsychotic NR across four UK sites. 
Cognitive performance was assessed using the Brief 
Assessment of Cognition in Schizophrenia (BACS).
Participants One hundred and six participants aged 
18–65 years with a diagnosis of schizophrenia or 
schizophreniform disorder were recruited according to 
their treatment response, with 52 NR and 54 R cases.
Outcomes Composite and subscale scores of cognitive 
performance on the BACS. Group (R vs NR) differences in 
cognitive scores were investigated using univariable and 
multivariable linear regressions adjusted for age, gender 
and illness duration.
Results Univariable regression models observed no 
significant differences between R and NR groups on any 
measure of the BACS, including verbal memory (ß=−1.99, 
95% CI −6.63 to 2.66, p=0.398) and verbal fluency 
(ß=1.23, 95% CI −2.46 to 4.91, p=0.510). This pattern of 
findings was consistent in multivariable models.
Conclusions The lack of group difference in cognition 
in our sample is likely due to a lack of clinical distinction 
between our groups. Future investigations should aim 
to use machine learning methods using longitudinal first 
episode samples to identify responder subtypes within 
schizophrenia, and how cognitive factors may interact 
within this.
Trail registration number REC: 15/LO/0038.
INTRODUCTION
Up to one- third of patients with a schizo-
phrenia diagnosis have inadequate symp-
tomatic improvement despite having at 
least two antipsychotic drugs, one being a 
second- generation antipsychotic excluding 
clozapine, at adequate doses and duration 
(4–6 weeks; National Institute of health and 
Care Excellence (NICE) guidelines)1 and are 
termed treatment resistant (TRS).2 3 Almost 
all guidelines recommend the antipsychotic 
clozapine in TRS4 with earlier clozapine 
treatment associated with better outcomes.5–8 
There is increasing evidence that TRS 
may represent a distinct subtype in schizo-
phrenia.9 10 Most treatment resistant cases 
exhibit antipsychotic non- response (NR) 
from the first episode with this observed in 
70%–84% of patients.3 11 An earlier age of 
onset has also been consistently associated 
with antipsychotic treatment resistance,12–16 
suggesting that TRS and NR may be associ-
ated with neurodevelopmental impairment. 
Identifying these underlying factors associ-
ated with antipsychotic treatment resistance 
Strengths and limitations of this study
 ► The study examined cognitive performance in a rel-
atively large and multicentre sample of antipsychot-
ic responders and non- responders.
 ► Cognition was assessed with the Brief Assessment 
of Cognition in Schizophrenia, a reliable and brief 
test battery specifically designed for schizophrenia.
 ► The lack of significant group differences in cogni-
tion between antipsychotic responders and non- 
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in schizophrenia is therefore important for improving 
prediction and early treatment of NR and TRS.
Cognitive impairment in schizophrenia may provide 
some insight into antipsychotic treatment response. 
Performance on tasks of verbal memory has often been 
reported to be impaired in schizophrenia samples,17 
those prior to medication initiation18 and at first 
episode.19 20 Indeed, impairments in verbal memory and 
language functions have also been reported in unaffected 
first- degree relatives of schizophrenia patients relative to 
healthy controls.21 22 Verbal memory and verbal working 
memory functions have also been reported to show a 
protracted maturation into adulthood, with impair-
ments in these functions observed in both early and late 
schizophrenia.23 This suggests a possibility of a genetic 
and cognitive continuum of risk in schizophrenia, which 
increases from controls to first- degree relatives, to treat-
ment responsive schizophrenia. A broader hypothesis is 
that treatment resistance is aetiologically continuous with 
treatment responsive schizophrenia but occupies a more 
exaggerated position on a continuum of neurodevelop-
mental liability.
In a recent meta- analysis comparing mostly cross- 
sectional studies of treatment resistant cases and 
responders, TRS cases exhibited greatest cognitive impair-
ments on tasks of verbal memory and learning (dl=−0.59, 
p<0.001) and language functions (dl=−0.53, p<0.001), 
with smaller but still statistically significant impairments 
in tasks across other cognitive domains, relative to their 
responder counterparts.24 However, this meta- analysis 
included an array of cognitive tasks, many with long test 
duration and stringent training requirements for raters. 
Short and comprehensive measures of cognitive perfor-
mance may aid in the detection of neuropsychological 
differences between antipsychotic responders (R) and 
non- responders (NR), while also being cost- effective. The 
Brief Assessment of Cognition in Schizophrenia (BACS)25 
was originally developed to be an easily administrable, 
brief, test battery that efficiently and specifically assesses 
cognitive deficits in schizophrenia cases. The measures 
included in the battery correspond to several cognitive 
domains with established deficits in schizophrenia, execu-
tive functions,26 27 working memory,28 29 motor/processing 
speed,30 verbal memory,31 32 verbal fluency33 34 and atten-
tion.35 36 If observable differences between antipsychotic 
R and NR are identified, this would further improve our 
understanding of cognitive factors implicated in the 
aetiology of antipsychotic response. Likewise, this would 
raise the possibility for future prospective research to use 
brief cognitive testing as part of predictive/diagnostic 
models for antipsychotic response and future treatment 
resistance.
Therefore, this cross- sectional study sought to assess 
the cognitive profiles of antipsychotic R and NR using the 
BACS. Based on the existing literature, we hypothesised 
that TRS patients would have poorer performance across 




The study used a cross- sectional design comparing anti-
psychotic treatment R and antipsychotic NR on cognitive 
performance.
Setting
The study was part of ‘Schizophrenia: Treatment Resis-
tance and Therapeutic Advances’ (STRATA), a consor-
tium which included King’s College London (London, 
UK), University of Manchester (Manchester, UK), Cardiff 
University (Wales, UK) and University of Edinburgh (Scot-
land, UK). The aim of the STRATA consortium is to iden-
tify neurobiological, cognitive and genetic biomarkers of 
antipsychotic treatment resistance and NR within schizo-
phrenia and other related psychotic disorders.
Patient and public involvement
During the early development of the study the views and 
recommendations of service users and carers regarding 
the use of stratified medicine research were assessed. 
Consultations were undertaken with the Institute of 
Psychiatry, Psychology and Neuroscience’s Service User 
Advisory Group. Service user researchers in London, 
Manchester and Edinburgh (18 people) carried out focus 
groups, and one carer focus group in London (8 people). 
Focus groups were digitally recorded, the transcripts 
analysed in NVivo V.10 using a simple thematic analysis, 
and quotations deidentified to protect participants. The 
results of this research are published in BioMed Central.37 
Both service users and carers reflected enthusiasm for 
stratified medicine. Each stage of the study was discussed, 
including their willingness to participate and attitudes 
towards, and perceived intrusiveness of different proce-
dures. These individuals also aided in commenting and 
providing recommendations on consent and participant 
information forms.
Participants
One hundred and six participants were recruited 
following a screening of patients across four sites: King’s 
College London (N=38), University of Manchester 
(N=32), Cardiff University (N=16) and University of 
Edinburgh (N=18). Inclusion criteria were as follows: 
aged 18–65 years, with a schizophrenia or schizophreni-
form disorder diagnosis as per Diagnostic and Statistical 
Manual of Mental Disorders, fifth edition38 criteria and 
be able to read and write English to a sufficient level 
(see also Egerton et al.39 Participants were excluded if 
they were pregnant, had ever experienced a head injury 
involving loss of consciousness for more than 5 min, met 
International Classification of Diseases (ICD) criteria 
for harmful substance misuse or a psychotic disorder 
secondary to substance use, scored <3 on the CRS (a 
measure of adherence)40 41 or had been treated with 
clozapine in the previous 3 months. All participants gave 
informed consent prior to enrolment.
 on N
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Definition of antipsychotic R and antipsychotic NR
Participants were defined as antipsychotic treatment R if 
they had been treated with only one antipsychotic drug 
since illness onset or if their antipsychotic drug had been 
changed only for reasons of adverse effects as opposed 
to NR. In addition to this, responders needed to have a 
Clinical Global Impression- Schizophrenia scale (CGI- 
SCH)42 of below 4 (moderately ill), a Positive and Nega-
tive Syndrome Scale (PANSS)43 total score below 60, and 
a CRS40 41 level of adherence greater than 3 (‘accepts only 
because compulsory’). Fifty- four treatment responders 
were recruited into the study.
Antipsychotic treatment NR was defined as having 
documented treatment with at least two antipsychotics 
each above the minimum therapeutic dose as defined by 
the British National Formulary for >4 weeks each, a CGI- 
SCH severity score of >3, a PANSS total severity rating of 
at least 70, and a CRS adherence score of >3. Fifty- two 
participants met criteria for antipsychotic NR.
MATERIALS
Clinical and demographic measures
Previous and existing drug use were measured using 
the Alcohol, Drug and Tobacco Inventory. Partici-
pants’ disorder severity was measured using the Mini- 
International Neuropsychiatric Interview (M- Psychotic 
Disorders; A- Major Depressive Episode; D- Manic/Hypo-
manic/Bipolar),44 Structured Clinical Interview- PANSS 
(SCI- PANSS)45 and CGI- SCH.42 Concordance with medi-
cation was assessed using the Clinical Rating Scale (CRS) 
for Schizophrenia.40 41 Participants also provided demo-
graphic data, such as years of previous full- time educa-
tion, age, gender, as well as information regarding their 
previous antipsychotic history which were supplemented 
by medical records.
Measures of cognitive performance
Cognitive data were collected using the BACS25 across 
all sites at the beginning of the assessment, following the 
administration of clinical and demographic measures. 
The battery is designed to take ~30 min to complete, 
with minimal training demands, and is designed to be 
easily administered by clinical and healthcare workers.25 
The BACS (version A)25 consists of six tests from the 
following cognitive domains: (1) Verbal Memory: List 
learning task; (2) Working Memory: Digit Sequencing 
task; (3) Motor Speed: Token motor task; (4) Verbal 
Fluency: Category instances task (Animals) and phono-
logical (F and S- words); (5) Attention and speed of 
information processing: Symbol Coding task; (6) Exec-
utive Functions: Tower of London task. All tasks on the 
BACS are scored with higher scores representing better 
performance. Composite z and t scores for the BACS 
are generated using normative data46 and the following 









3.63   with 
each measure’s z score summed and the total divided by 






All analyses were conducted using STATA V.15/SE.47 
χ2 tests were used to compare cognitive performance 
across sites in case of site differences. Univariable regres-
sions were used to compare cognitive performance 
between groups. Multivariable regression analyses were 
used to adjust univariable results for age, gender and 
illness duration, due to the reported relationship of 
age,48 49 gender50 51 and illness duration52 53 with cognitive 
outcomes. Analyses adjusting for anticholinergic effects 
of antipsychotic medication are presented in online 
supplemental material (online supplemental table S1).
RESULTS
Descriptive statistics of demographic and clinical variables 
between responder groups are reported in table 1. In the 
antipsychotic R group (N=54), four were treated with a 
first- generation antipsychotic. For the NR group (N=52), 
five were treated with a first- generation antipsychotic. All 
other participants were treated with second- generation 
antipsychotics.
Cognitive performance
Mean scores for each group on all BACS tasks and stan-
dardised composite scores are displayed in table 2. All 
measures of the BACS were normally distributed, with 
exception of the Tower of London task which was moder-
ately negatively skewed (skewness=−0.95) as per the 
guidelines from Bulmer.54 Cognitive performance on 
BACS composite and subtests did not significantly differ 
by site where data were collected.
Univariable linear regression analyses (table 2) observed 
no significant relationships between response status and 
BACS performance. Multivariable models adjusted for 
age, gender and illness duration also observed no signifi-
cant relationships between response status and cognitive 
outcomes (table 2).
DISCUSSION
The present investigation sought to compare specific 
cognitive deficits in antipsychotic R and antipsychotic 
NR using the BACS,25 anticipating the greatest deficits 
for NR in measures of verbal memory and verbal fluency 
when compared with R. Unlike previous cross- sectional 
studies,55–62 this investigation identified no significant 
differences in cognitive performance between groups.
Previous cross sectional research investigating differ-
ences in cognitive performance between antipsychotic 
treatment R and treatment resistant cases have identi-
fied poorer performance in verbal, executive function, 
full- scale IQ cognitive measures,55 56 59–61 and verbal 
memory55 58 60 62 63 in treatment resistant patients. A recent 
study using a similar methodology and sample size to ours 
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also failed to show significant differences between antipsy-
chotic R and TRS cases on individual tasks of the BACS64 
but did observe significant differences on standardised (z 
and t) composite scores suggesting overall impairment 
in the TRS group. Our additional analyses also adjusting 
for anticholinergic effects (online supplemental table 
S1) also observed no change to the relationship between 
BACS and antipsychotic response, suggesting no medica-
tion effects on our findings. We also further restricted our 
analysis to exclude participants that were under dosed 
(ie, not within the 150–600 mg/per day range) removing 
12 participants (R=5, NR=7). No change was observed in 
the pattern of results.
The lack of significant differences in cognitive perfor-
mance observed between R and NR groups in our study 
may be partly explained by the criteria used to define 
these groups. Unlike earlier investigations, our study did 
not include clozapine- treated patients, and there may 
have been less clinical separation between the R and 
NR groups than in some previous studies (as discussed 
in Egerton et al).39 Furthermore, in our cross- sectional 
study design, it is not possible to determine the propor-
tion of participants in the NR group who would meet 
criteria for TRS.65 It is, therefore, possible the NR group 
was less severely unwell as in some previous studies, 
which may have reduced the ability to observe poten-
tial impairments in cognition due to clinical overlap. 
Previous investigations which observed group differ-
ences in cognitive performance between R and TRS 
included patients prescribed clozapine,56 57 59–61 63 64 
and reported higher PANSS positive, negative and total 
scores,59 60 64 suggesting the NR/TRS groups may have 
had greater illness severity compared with our sample. 
Likewise, demographic and clinical variables previously 
found to be associated with antipsychotic R, such as a 
younger age and age of illness onset in NR,12–16 did not 
differ between treatment R and NR in our sample, again 
suggesting group that compared with previous investiga-
tions, there was not enough clinical separation between 
our samples. In addition, the power calculations for 
sample size were generated on the basis of being able 
to provide >95% power to detect differences in levels of 
Table 1 Demographic and clinical characteristics by group
Demographic/clinical variable
R NR
N Mean/ratio SD N Mean/ratio SD
Age 54 29.52 9.36 52 29.99 8.50
Gender (male:female) 54 46:8 – 52 43:9 –
Age of illness onset 53 26.10 6.53 50 25.31 5.93
Illness duration since first antipsychotic (years) 53 3.71 6.87 50 5.03 5.79
Duration from first psychotic symptom (years) 54 4.81 7.53 52 5.50 6.13
Duration from first contact with mental health 
services (years)
54 4.04 7.49 52 5.40 6.34
Full time education (years) 53 13.09 2.37 50 12.88 2.75
Chlorpromazine equivalents (mg/day) 53 305.45 146.86 52 343.73 202.83
PANSS positive score 54 12.24 3.40 42 22.65 3.54
PANSS negative score 54 13.82 3.38 52 20.96 4.56
PANSS total score 54 53.46 7.91 52 87.29 9.30
CGI positive symptoms score 53 3.26 0.76 52 5.50 0.10
CGI negative symptoms score 53 3.21 0.86 52 4.88 1.04
CGI cognitive symptoms score 53 3.08 0.83 52 4.83 1.22
CGI overall severity 53 3.42 0.75 52 5.48 0.58
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anterior cingulate glutamate39 (see Protocol provided 
in online supplemental material) and it is possible that 
the sample was underpowered to detect neurocognitive 
differences using the BACS.
It is also possible that our definition of antipsychotic 
response and inclusion criteria may have influenced our 
findings. As per definition, differences were only observed 
between groups on CGI- SCH and PANSS measures of 
symptom severity. Psychotic symptoms such as halluci-
nations, delusions and paranoia (ie, schizophrenia- like 
symptoms) have been attributed to D2 dopamine recep-
tors and functioning in the striatum, as evidenced by 
animal models.65 It has also been reported that following 
amphetamine administration, hyperactivity of dopamine 
transition is associated with the activation of psychotic 
symptoms. However, amphetamine induced psychosis 
does not tend to exhibit negative and cognitive symp-
toms.66 In contrast, cognitive deficits in schizophrenia 
have been reported to be related to functioning in the 
dorsolateral prefrontal cortex (DLPFC),67 68 glutamate 
to Gamma Aminobutyric Acid (GABA) ratios in the 
DLPFC,69 as well as prefrontal glutamate levels in the 
dorsal anterior cingulate cortex in antipsychotic- naïve 
patients.69 Unlike psychotic symptoms, the Dopamine D1 
receptor signalling is essential for cognition.70 Therefore, 
it is possible that the differences in the neurobiological 
underpinnings between psychotic and cognitive symp-
toms may also explain why no cognitive differences were 
observed between groups, as this was biased in favour of 
psychotic symptoms due to our inclusion criteria.
Another consideration is that our study focused on 
younger patients early in their treatment trajectories to 
reduce the potential effects of chronicity and previous 
medication, with a mean length of treatment of 3–4 years. 
Most previous cross- sectional investigations also include 
older samples with a longer duration of illness,56 57 59 60 64 
although differences in measures of verbal intelligence 
and fluency have been quantifiable at the first episode 
in treatment resistant psychosis.27 Trajectory modelling 
of cognitive performance in first episode psychosis has 
observed deficits in executive function performance, 
relative to controls, with these remaining stable over 
illness duration.71 However, deficits in verbal knowledge 
and memory became more apparent and exaggerated 
relative to controls following the first episode.72 Similar 
exaggerated declines following the first episode have also 
been observed in measures of verbal memory.71 73 With 
our sample of patients being early in their treatment, 
cognitive deficits may have been less marked at this illness 
stage.
Likewise, this more restricted focus may explain why 
there was smaller sampling of females in comparison to 
previous investigations. A recent nationwide cohort study 
found that on average females are more likely to be first 
diagnosed with a mood disorder prior to a psychotic diag-
nosis.74 This coupled with the observation that females 
also tend to have a later onset of psychotic symptoms than 
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may have restricted the true picture of schizophrenia at 
large within the general population.
Despite not detecting significant differences between 
antipsychotic R groups, it is worth mentioning the impor-
tance of conducting research using clinically transferable 
measures of cognitive impairment. It may be possible for 
future researchers to use machines learning algorithms 
to identify subgroups of schizophrenia from cognitive 
outcomes. Bak et al76 used Gaussian mixture modelling to 
identify two distinct subgroups in antipsychotic- naive first 
episode schizophrenia samples. In this study, cognitive 
and electrophysiological data were used to identify the two 
groups. When predicting treatment response, assessed by 
the PANSS, there was a significant predictive relationship 
between group and antipsychotic response. Therefore, 
future research should aim to use more machine learning 
techniques to identify patterns of cognitive performance 
within schizophrenia subsamples and investigate antipsy-
chotic response between these groups.
CONCLUSIONS
Within this cross- sectional investigation, we observed 
no differences in cognitive performance between anti-
psychotic R and NR. This may be because there was less 
clinical separation between these groups in our sample in 
comparison to previous investigations. Future investiga-
tions should consider the role of machine learning tech-
niques to investigate the role of cognitive functions in 
identifying subgroups of schizophrenia using first episode 
cohorts and how this may differ in future stages of treat-
ment resistance. Such research using antipsychotic- naïve 
patients vs healthy controls has observed strong group 
discrimination using cognitive measures in comparison 
to electrophysiology and MRI methods,77 with other 
investigations observing distinct subgroups in schizo-
phrenia from differences in early information processing 
and higher cognitive functions.74
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Study Synopsis 
 
Full Title   
 
Investigating factors associated with response to 
antipsychotic treatment  
Short Title/Acronym   
STRATA 
 
Protocol Version number and Date 
 
 Version  4.0, 19th August 2016 










 Kings College London / South London and Maudsley 










 The principle objective is to use Positron Emission 
Tomography (PET), Magnetic Resonance 
Spectroscopy (MRS), genetic and clinical data to 
confirm recent evidence of a distinct subtype of 
schizophrenia, based on differences in dopamine and 
glutamate function which would lead to developing a 
clinically useful, acceptable and cost-effective 
stratification tool. 
 
Secondary objective (s) 
 
 To establish a lasting network of academia and 
industry partners and patients databases to facilitate 
and expedite both follow-up and novel research built 
to address patient stratification. 
 
To examine and improve test-re-test and intercentre 
reliability of neuroimaging procedures for future large 
scale multisite studies in this mould that will be 
conducted. 
Number of Subject  100 
 
Main Inclusion Criteria 
 
 aged 18-65;  
DSM 5 schizophrenia/schizophreniform disorder. 
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Statistical Methodology and Analysis 
 
 Summary statistics will be used to describe the 
demographic and clinical characteristics of each 
participant group. 
 
Group differences in demographic, clinical variables 
and 18F-DOPA Ki and glutamate concentration will be 
determined using pre-specified between group 
comparisons as appropriate (e.g. Chi square; 





BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2021-054160:e054160. 11 2021;BMJ Open, et al. Millgate E
STRATA: Investigating factors associated with response to antipsychotic treatment  
Protocol. Version 4.0, 19th August 2016 
REC REF: 15/LO/0038  
  
 Page 6 of 15 
 
1. Introduction 
People with schizophrenia suffer from a range of symptoms including hallucinations (such as 
hearing voices), delusions (false beliefs) and thought disorder (thoughts not flowing in a logical 
way), as well as 'negative symptoms' such as a lack of motivation and withdrawal from social 
contact. Currently, antipsychotic medication is the mainstay of treatment for schizophrenia and all 
existing antipsychotic medications are thought to work by acting to reduce transmission of a brain 
chemical called dopamine. However, even after attempts to treat the disorder with two different 
antipsychotics, around 30% of patients still fail to improve. When this happens, the medical 
guidelines recommend treatment with a different drug called clozapine. However clozapine has 
several side effects and requires regular blood tests, so people do not like taking it. It is also 
ineffective in some patients. 
 
The result is that a large number of patients spend too long on ineffective drugs which impact 
greatly on their mental health, well-being and quality of life whilst the cost of ineffective treatment 
is a huge financial burden to the NHS, consuming 25-50% of the total national mental health 
budget. 
 
STRATA (funded by a £5M Medical Research Council award) aims to build on new evidence from 
neuroimaging and genetics studies suggesting that those who do not respond may actually have 
a completely different neurochemical abnormality causing their symptoms (the same sort of 
symptoms as are caused by excessive dopamine), involving a different chemical called glutamate. 
There are some new medicines under development that we hope will help people whose illness 
has not responded to standard medicines acting on dopamine. 
 
We aim to develop a method to predict, even as early as when first seen, which patients will 
respond to standard dopamine drugs, and which people are instead more likely to respond to the 
new glutamate drugs. This will allow people to receive the medicines they need straight away, 
without having to try ineffective drugs first. 
 
The proposed research programme is broken down into several parts. This protocol describes 
the first study, which is a UK, multicentre study using brain scans to confirm that those patients 
who don't respond to standard treatments have higher glutamate levels, but lower dopamine 
levels than those who respond well. This information, along with clinical and genetic information, 
will be used to develop tests to identify in advance which people will respond to dopaminergic 
versus glutamatergic medication.  
 
2. Study Objectives and Design 
2.1. Study Objectives and Outcomes 
The principle objective is to use Positron Emission Tomography (PET), Magnetic Resonance 
Spectroscopy (MRS), genetic and clinical data to confirm recent evidence of a distinct subtype of 
schizophrenia, based on differences in dopamine and glutamate function which would lead to 
developing a clinically useful, acceptable and cost-effective stratification tool. 
 
The secondary research objectives are: 
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i) To establish a lasting network of academia and industry partners and patient databases to 
facilitate and expedite both follow-up and novel research built to address patient stratification. 
 
ii) To examine and improve test-re-test and intercentre reliability of neuroimaging procedures for 
future large scale multisite studies in this mould that will be conducted. 
 
The study is designed to generate a predictive test for treatment response so the outcome will be 
the overall measure generated.  The data that will lead to this will include MRS glutamate level, 
the PET Ki value, polygenic risk score and clinical variables such as PANSS score. 
 
2.2 Study Design  
STRATA is a multi centred study. 100 participants will be recruited across 4 university research 
sites including KCL, University of Manchester, Cardiff University, and University of Edinburgh. 
 
Participants will consent to all aspects of the study including interviews/assessments, blood and 
urine sampling, MRI scan and PET scan (the latter in London and Manchester only) but can also 
choose to opt out of some tasks if necessary. 
 
1. Assessments 
An initial interview will collect demographic and personal information (e.g. address, contact 
details, date of birth, gender, handedness, head injury and other relevant medical history), and 
structured assessments of medication history and response. Clinical information will also be 
recorded from medical records. The Mini International Neuropsychiatric Interview (MINI) will be 
used to confirm diagnosis, which takes around 15 minutes to complete. 
 
Illness severity will be measured using: 
i. Positive and Negative Syndrome Scale (PANSS),  
ii. Clinical Global Impression scale (CGI -SCH)  
iii. Kemp Clinician Rating Scale (of adherence to treatment) 
iv. Brief Assessment of Cognition in Schizophrenia (BACS) 
 
2. Biological samples 
Blood samples will be collected via cannula (as described under the PET scan section below) or 
by venous puncture, during a routine blood sample whenever possible. The participant will give 
up to 50ml in blood (around 3 tablespoons), this is in line with sampling guidelines.  
 
While the biological sample collection is ongoing, samples will be stored at the laboratory 
corresponding to each research site. The samples for genetics analysis will subsequently be 
transferred to the MRC Center for Neuropsychiatric Genetics and Genomics, Cardiff University. 
 
KCL/South London and the Maudsley (SLaM) participants will also be invited to participate in the 
BRC Biobank. This is covered by a separate ethical approval (09/H0606/84 NRES Committee 
South Central-Oxford C.) 
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Participants will be asked to provide samples (urine and blood) for metabolomics analysis. This 
will be processed at MRC-NIHR National Phenome Centre. The Centre is funded 
by the MRC and NIHR and led by Imperial College London and King's College London. 
 
As of April 2016, participants will also have a sample taken for proteomic analysis. These samples 
will be sent to the University of Manchester (Molecular Pathology Innovation Centre). This will be 
within the 50ml sampling guideline already approved. 
 
3. Magnetic Resonance Imaging (MRI)  
The MRI scans (100 in total) will take place at four locations (London, Cardiff, Manchester and 
Edinburgh) at NHS Trust or University sites. The MRI session will last a maximum of 1 hour. 
During the scan, participants will be asked to lie flat on their back with their head inside the 
scanner. The scanner makes a loud noise as it takes pictures, so participants will be given 
headphones to wear and asked to lie as still as possible. The researcher will be able to speak to 
the participant over the microphone throughout and participants will be told if they do feel 
uncomfortable the session can be stopped at any time. The MRI scan itself is painless and safe.  
Some people find scans claustrophobic or anxiety-provoking, and we have a mock scanner that 
participants can try out first. The scanner consists of a powerful magnet, which may attract metal 
objects.  Therefore before the scan participants will go through a safety questionnaire, to check 
that they can have the scan. If a participant has any metal in their body, either from accidents or 
operations, they may not be able to have the MRI scan, but they can still take part in the rest of 
the study.   
 
All data collection will occur at 3 Tesla. During the scan, data acquisition will include acquisition 
of localizer, T1-weighted and T2-weighted structural scans. 1H-MRS data for measurement of 
regional concentrations of glutamate and other metabolites present in the 1H-MRS spectra will 
be acquired using conventional PRESS (Point RESolved Spectrocopy) acquisition routines, as 
well as a resting state fMRI sequence if time allows. 
 
Due to change of scanner at Cardiff University, participants recruited in Cardiff prior to the 
decommissioning of the old scanner will be re-contacted and asked whether they would volunteer 
for a second MRI scan on the new scanner. They will also be asked to repeat some of the 
interview/assessments and may be asked for biological samples (only in circumstances where 
these were not provided previously). Participants will be reimbursed for their time at the same 
rate. 
 
In the unlikely event that MRI scanner issues or excessive movement make the MRS data 
unusable at other sites, participants can be re-contacted and asked whether they would like to 
volunteer for a second scan. 
 
4. Positron Emission Tomography (PET)  
The PET scans (60 in total, subset of those having MRI scans) will take place at two sites: 
i) Imanova Limited, Imperial College London, Hammersmith Hospital in London. 
ii)The Wolfson Molecular Imaging Centre in Manchester.  
 
PET with the radiotracer 18F-DOPA will be used to assess brain dopaminergic function in a sub-
set of participants (N=60) recruited at KCL and University of Manchester. The PET scan 
procedure involves an initial transmission scan followed by a dynamic scan lasting approximately 
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90 minutes after injection of the radiotracer 18F DOPA through a cannula inserted into an arm 
vein. In the event the participant has to get off the scanner e.g. to go to the toilet or for some other 
reason then the transmission scan may be repeated to reposition them in the camera. In the 
unlikely event of technical failure prior to or during the PET scan the subject will be invited back 
for a replacement session (the total dose will then be ~7.5mSv, and the risks of this will be 
explained). 
 
In Manchester, participants will be offered the option of having an extra, High Resolution 
Research Tomograph (HRRT) scan after their main STRATA PET scan (after a 15 minute comfort 
break). This will be between 30-60 minutes depending upon participant tolerability. Due to the 
long half-life of 18F and the slow removal of 18F from the brain, this extra scan will not involve 
any further injection of radiotracer. Another transmission scan will be carried out for attenuation 
correction purposes although this will be of very low radiation dose (0.02mSv). In the event of 
significant head movement during the HRRT scan, this transmission scan may be repeated. 
 
In order to minimise the peripheral breakdown of 18F-DOPA, an oral dose of 150mg carbidopa 
and 400mg entacapone will be given one hour prior to the scan. Very few people experience any 
side-effects from these. Very occasionally people experience stomach upset, muscle movements, 
dry mouth and/or an orange tinge to their urine from the tablets, which may last a few hours to a 
day. This permits the use of a lower dose of 18F-DOPA than would otherwise be necessary.  
Participants will be asked to refrain from eating, drinking (apart from water) and smoking from 
midnight on the night before the scan, until after the scan is finished. This is because large amino 
acids may affect brain uptake of 18F-DOPA. Participants will also be instructed not to take illicit 
drugs (such as cannabis or cocaine) in the prior three days. Before the scan we will ask for a 
urine sample to check whether substances that can affect the scan are in their system. Women 
of childbearing age will have a pregnancy test and will be required to use regular contraception 
prior to the scan. At the start of the scan we will give participants a radiotracer (which is mildly 
radioactive) to measure the brain dopamine system.  At the end of the scan the cannula will be 
removed from their arm.  
 
Participants taking part in a PET scan at Imanova (SLaM/KCL participants) will have an additional 
1-2 tablespoons (up to 30ml) of blood taken through their cannula to measure natural blood 
chemicals (hormones and genes) that are connected to dopamine function.    
 
Participants taking part in a PET scan in Manchester will have all their bloods taken at this point 
(up to 50ml) as described under ‘Biological Samples Section’, whenever possible. 
 
3. Sample Size, Statistics, Selection and Withdrawal of Subjects 
The patients will be identified by members of the clinical team. Only the clinical team (who may 
also be part of the research team with NHS honorary contracts) will be able to access participant 
records and data prior to consent. No patient records will be screened by study researchers prior 
to consent. Study researchers will have access to patient records after/ if participants have 
consented to this.   
We will recruit a total of 100 participants. Potential participants may be referred via clinical teams 
or other research studies/existing databases with consent to re-contact or registries and 
recruitment initiatives in NHS Trusts whose terms are in accordance with NHS Trust policies. 
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Participants will be first approached by a member of the clinical team or a member of the research 
team, with approval from the clinical team/ other study 
Inclusion Criteria 
1) aged 18-65;  
2) DSM 5 schizophrenia/schizophreniform disorder.  
3) Participants must read and write in English at a level sufficient to understand and 
complete study-related procedures 
Exclusion Criteria 
1) Pregnancy;  
2) Severe head injury involving loss of consciousness >5 minutes (ever); 
3) Meeting ICD criteria for harmful substance misuse or psychotic disorder secondary 
to substance misuse; 
4) Participation in MRI scans requires exclusion of contraindications to MRI at 3 tesla 
e.g. metallic or electronic implants;  
5) Severe claustrophobia. 
6) Treatment with clozapine in the last 3 months 
To establish and confirm the stratifier 1H-MRS data will be acquired in a total of 100 patients early 
in the course of their treatment; 50 T-Resp and 50 T-NonResp; matched for chronicity of illness.   
 
Operational definition of T-Resp: 
(i) treatment with only one antipsychotic drug since onset, or treatment changes have been 
due to adverse effects, not for non-response. (ii) CGI-SCH severity score of <4; (iii) PANSS total 
<60 (Leucht 2005); (iv) CRS >3 
 
Operational definition of T-NonResp: 
(i) documented treatment with at least two antipsychotics each above the minimum therapeutic 
dose as defined by the BNF for >4 weeks each; (ii) despite ongoing treatment and adequate 
adherence (assessed by iv) a CGI-SCH severity score of >3; (iii). PANSS total severity rating of 
at least 70 iv) Clinician Rating Scale (CRS; a measure of adherence) (Kemp et al 1996) >3. 
 
Power and sample size calculation: 
The study is powered to give >95% power to detect differences found in Egerton et al 2012 
(α=0.05, allowing for 10% loss of sensitivity due to combining data from multiple centres).  We 
have more than 80% power to detect a significant difference between a ROC curve with AUC 0.7 
and chance, assuming α=0.05, 2-tailed.   Two-tailed 18F-DOPA PET data will be acquired in a 
subset at 2 sites (N=60) to determine if the double dissociation between DA function and GLU 
function we have seen in chronic patients is also evident early in the illness course, where the 
strategy is most likely to be used (T-Resp n=30, T-NonResp n=30; powered to give >95% power 
to detect differences found in Demjaha et al 2012; α=0.05, allowing for 10% loss of sensitivity due 
to combining data from multiple centres). 
 
Summary statistics will be used to describe the demographic and clinical characteristics of each 
participant group. 
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Group differences in demographic, clinical variables and 18F-DOPA Ki and glutamate 
concentration will be determined using pre-specified between group comparisons as appropriate 
(e.g. Chi square; Fischer’s Exact; ANOVA).  
Missing data will be minimal given that data is being collected prospectively. The exact reason for 
the missing data will be recorded. Any blank measures or spurious data will be checked against 
the paper copy of the CRF stored securely at sites.  
Participants will be clearly told they can withdraw from the study at any time without having to 
give a reason. This is clear in the information sheet and the researcher will also explain this 
verbally to participants during the informed consent process . If a participant wishes to withdraw 
from a study all their identifiable data will be destroyed. Data or tissue already collected with the 
consent, which is not identifiable, would be retained and used in the study. No further data or 




We will recruit up to 15 healthy volunteers aged 18-65 to be scanned at each PET site (two sites; 
Imanova Limited, Imperial College London and The Wolfson Molecular Imaging Centre in 
Manchester) and 10 healthy volunteers aged 18-65 to be scanned at each MRI site (4 sites). This 
is to determine inter-site scanner variability and to provide normal range data for comparison with 
the clinical groups. In addition to the exclusion criteria above, healthy volunteers will be excluded 
if there is a history of schizophrenia or other psychotic disorder. Healthy volunteers will be 
recruited using an existing database of interested potential participants held at KCL. 




1) Participants will be first approached by a member of the clinical team or a member of the 
research team, with approval from the clinical team. 
2) The study will be described verbally to potential participants and they will be given a copy 
of the information sheet. They will be encouraged to ask questions about the research. 
Potential participants will be allowed as much time as they require to make a decision and 
at least 24 hours so they are able to seek advice from others about participation, including 
previous participants in the research where possible.  
3) If a patient expresses an interest in taking part, capacity to consent will be assessed and 
documented by the research team, in consultation with the clinical team. 
4) If the patient has capacity to consent and agrees to participate in the study, they will be 
asked to sign and date two copies of the consent form. One copy will be kept by the 
participant and one by the research team. The research team will pass onto the clinical 
team to scan into medical notes, or incorporate in paper notes.  
5) The participant will be informed that they can withdraw consent at any time, and without 
giving a reason. 
6) Participants will be informed they are to be compensated for their time and travel 
expenses. This monetary amount will be up to £120 (£145 in Manchester) depending on 
which parts of the study the participant is involved with.  
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Within Avon and Wiltshire Mental Health Partnership NHS Trust, Everyone Included will be used 
to identify potentially eligible participants. Potentially eligible participants are identified based on 
the study inclusion /exclusion criteria, excluding those who have declined to receive information. 
This is done via an automated search of the Trust’s electronic patient record system (RiO). An 
authorised search will be requested by a member or the R&D department, who are part of the 
clinical team and carried out by a member of the Information Analysis team. A data set is returned 
directly to the Everyone Included Administrators for processing the letters. No patient identifiable 
data will ever leave the Trust or be accessed by an external research team during this process. 
 
The ‘Research Opportunity Letter’ will be sent to these individuals. The letter itself will not contain 
any patient identifiable or disclosing information (such as making reference to their diagnosis or 
medications). It will provide a free-post return slip and contact details (phone, email, website, 
postal address) inviting individuals to get in touch if they would like to further information / to take 
part. The onus is on the individual to express an interest, otherwise no further action is taken.  
 
Upon responding to the ‘Research Opportunity Letter’, a Participant Information Sheet will be 
provided. If the research team is external, the individual will be asked if they are happy for their 
details (i.e. name and phone number) to be passed directly to the research team. No information 
is ever accessed by or passed to an external research team without first gaining permission from 
the potential participant. At this point standard study recruitment processes proceed. 
 
 
Risks and burdens 
The questionnaires involve personal questions and recalling experiences that some people may 
find distressing. Participants will be told if they feel uncomfortable with any of the questions they 
do not have to answer them.  
 
Blood sampling and placing the cannula can cause some discomfort, and there is a possibility 
that a small bruise may develop. This task will be performed by research workers trained in 
phlebotomy. Any risks of infection will be contained by using standard sterile procedures and the 
risks associated with this task will be the same as for any other blood sample collection. 
 
Any participants who become distressed during any procedure involved in this study will be 
encouraged to pause and will be reminded routinely that they can withdraw from the study at any 
time without a reason or penalty.  
 
Any clinically significant issues that may arise during the assessment, the verbal consent will be 
obtained from the patient to pass onto the responsible psychiatrist or other relevant member of 
the staff. This will always be done with the participants’ permission and will only be breached in 
the rare cases when there is judged to be an issue of safety, for example if the participant 
makes specific threats towards an individual.  
 
Imaging 
The MRI and PET scans themselves are painless and safe. Some people find the scans 
claustrophobic or anxiety-provoking. There is a mock scanner that participants can try out first if 
they wish. Participants will be told if they feel uncomfortable the scanning can be stopped at any 
time. Before the scan we will go through a safety questionnaire, to check that participants can 
have the scan. If they have any metal in their body, either from accidents or operations, they may 
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not be able to have the MRI scan, but they can still take part in the rest of the study. Clinical 
Research workers and research workers will log screening results. 
 
Very occasionally people experience side effects from the medication they receive when taking 
part in a PET scan. These side-effects can include stomach upsets, muscle movements, dry 
mouth and/or an orange tinge to their urine. These side-effects may last a few hours to a day but 
participants will be warned about this and told it is nothing to worry about. 
 
PET scans involve a small amount of radiation.  Any exposure to radiation carries a risk of 
damaging the body's tissues and possibly triggering cancer at a later date. However, the risk is 
very small.  A standard PET scan in this study will expose participants to 3.7mSv, (this may be 
3.72mSv in Manchester if participants decide to have the extra, high resolution PET scan),  which 
is the same amount of radiation that they are exposed to from natural sources of radiation, such 
as the sun, over the course of 18 months. In extremely rare cases the PET scan may need to be 
repeated and we have ARSAC approval for a maximum of 7.5mSv exposure per participant.  Most 
experts believe that the risk of cancer developing only becomes significant in people who are 
exposed to 100mSv or more. However, as a precaution we are excluding pregnant or 
breastfeeding women. A pregnancy test will be carried out on female urine samples before the 
PET scan is conducted. Participants will be asked to consent to this on the consent form. Clinical 
Research workers and research workers will log screening results and ensure participants will not 
be exposed to more than 10mSv in 12 months (ARSAC guidelines suggest 10mSv as the normal 
upper limit for radiation exposure related to research procedure) 
5. Sample handling and laboratories  
Biological sample collection tubes and barcodes will be sent to sites in advance from the MRC 
Center for Neuropsychiatric Genetics and Genomics, Cardiff University. Samples will be stored in 
laboratories at sites and transportation will be organized when required (likely at 6 monthly basis, 
dependent on recruitment). Details of sample collection and storage at site will be recorded. Study 
SOPs will describe collection and storage specifications to ensure all sites are following the same 
guidelines. 
 
When samples arrive at Cardiff University, researchers will ensure that the physical integrity of 
these samples have not been compromised in transit and track the samples in using their 
barcodes. The research team at Cardiff will notify the sponsor and the other study teams of any 
issues in transportation. 
 
Cardiff University will extract DNA from the blood. We will perform genome-wide and targeted 
genotyping and/or exome or whole genome sequencing. We will seek genetic association with 
the imaging and other outcome measures at the level of individual genotype/sequence variant, 
genes, gene sets/pathways and polygenic or other summary scores.  
 
A urine and blood sample will undergo metabolomic analysis at MRC National Phenome Centre. 
The Centre is funded by the MRC and NIHR and led by Imperial College London and King's 
College London. An additional blood sample will undergo proteomic analysis at the University of 
Manchester. 
 
KCL/South London and the Maudsley (SLaM) participants will also be invited to participate in the 
BRC Biobank. This is covered by a separate ethical approval (09/H0606/84 NRES Committee 
South Central-Oxford C.) 
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6. Assessment of Safety  
There are no serious adverse events expected to occur during the study. 
 
All blood samples will only be taken by researchers trained in phlebotomy. All risks are the same 
as for any routine blood sample and are therefore minimal. 
 
The drugs administered and the radiotracer used for the PET are standard procedures. The drugs 
administered may cause stomach upsets, muscle movements, dry mouth and/or an orange tinge 
to their urine. These side-effects may last a few hours to a day but participants will be warned 
about this and told it is nothing to worry about. Female participants will have a pregnancy test in 
advance.  
 
For MRI scans a safety questionnaire will be carried out prior to the scan to check the participant 
does not have any metal in their bodies from operations or accidents. 
 
7. Study oversight arrangements  
STRATA is a multi-centred study and this will be managed by attendance at a monthly Consortium 
Executive meeting which will be responsible for the effective oversight of the daily activities of the 
study. Quarterly Consortium Board (CB) teleconferences will oversee the progress of, and 
interaction between, the workstreams to maintain communication of issues and progress between 
sites across the different aspects of STRATA.  The CB will submit six-monthly Programme reports 
to the funder, MRC. 
 
The project team consists of a full time Project Manager based at the IoPPN, KCL and a 50% 
Project Manager at the University of Manchester.  
 
8. Ethics & Regulatory Approvals 
REC name and address: South East Coast-Surrey Research Ethics Committee, Whitefriars, Level 
3, Block B, Lewins Mead, Bristol, BS1 2NT 
 
This study has also been reviewed and approved by the Administration of Radioactive 
Substances Advisory Committee (ARSAC). 
 
9. Data Handling 
Once participants have consented to be in the study some personal details will be taken. These 
details will be taken by the researcher with full consent to do so. These details will be kept securely 
at sites and used to contact patients when required to make appointments. No personal data will 
be shared with anyone outside of that study team. Each participant will be given a unique identifier 
and any clinical or genetic or imagining data relating to the same participant will link via that code. 
 
Data will be entered and stored on a secure web application called Research Electronic Data 
Capture (REDCap). REDCap will not store any personal details and all participants will have a 
unique non-identifiable ID code. This unique ID code will then be used to merge all processed 
imaging, genetics and clinical data. REDCap will be hosted on secure servers at the Biomedical 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2021-054160:e054160. 11 2021;BMJ Open, et al. Millgate E
STRATA: Investigating factors associated with response to antipsychotic treatment  
Protocol. Version 4.0, 19th August 2016 
REC REF: 15/LO/0038  
  
 Page 15 of 15 
Research Centre at Kings College London. All sites can access REDCap for the purposes of data 
entry via a web browser and data is uploaded when a WIFI signal is available. 
 
The CI will ensure that the trial is conducted in compliance with the principles of the Declaration 
of Helsinki (1996), and in accordance with all applicable regulatory requirements including but not 
limited to the Research Governance Framework, Trust and Research Office policies and 
procedures and any subsequent amendments. 
 
 
10.  Finance and Publication Policy 
STRATA is funded by a £ £4,900,000 Medical Research Council grant. Kings College London will 
receive and manage this funding. A collaboration agreement has agreed budgets between sites. 
 
Analysis and findings from the study will be published as papers in journals. No identifiable data 
will be included. 
 
This study has been adopted onto the UKCRN Portfolio and the research project will be registered 
on their database which is publicly available. 
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Univariable and multivariable linear regression models for response status and BACS performance 
 
 
Note. R = antipsychotic responder; NR = antipsychotic non-responder; BACS = Brief Assessment of Cognition in Schizophrenia; CIs = confidence intervals. 
 
R NR Unadjusted Adjusted for age, gender, illness 
duration and anticholinergic effects 
Adjusted for anticholinergic effects 
BACS measure N N β  SE 95%CI P-value β  SE 95%CI P-value β  SE 95%CI P-value 
Verbal Memory 53 50 -1.99 2.34 -6.63 ; 
2.66 
.398 -3.18 2.38 -7.90 ; 
1.54 
.185 -2.34 2.35 -7.00 ; 
2.32 
.322 
Digit Sequencing 53 50 0.11 0.90 -1.67 ; 
1.89 
.901 0.07 0.92 -1.76 ; 
1.89 
.944 -0.02 0.90 -1.81 ; 
1.77 
.983 
Verbal Fluency 53 50 1.23 1.86 -2.46 ; 
4.91 
.510 1.08 1.94 -2.78 ; 
4.94 
.580 1.17 1.88 -2.56 ; 
4.90 
.536 
Token Motor  53 49 -0.42 2.95 -6.28 ; 
5.43 
.886 -1.40 2.97 -7.29 ; 
4.50 
.638 -0.62 2.99 -6.56 ; 
5.31 
.835 
Symbol Coding  53 50 -1.84 2.28 -6.37 ; 
2.68 
.421 -1.89 2.37 -6.60 ; 
2.83 
.428 -2.04 2.30 -6.60 ; 
2.53 
.378 
Tower of London  53 50 0.40 0.82 -1.23 ; 
2.03 
.625 0.35 0.84 -1.30 ; 
2.01 





53 49 -0.03 0.29 -0.60 ; 
0.54 
.922 -0.08 0.30 -0.68 ; 
0.52 
.798 -0.07 0.29 -0.65 ; 
0.50 
.800 
t score composite 53 49 -0.64 2.87 -6.32 ; 
5.05 
.825 -1.33 3.02 -7.32 ; 
4.67 
.662 -1.24 2.88 -6.96 ; 
4.48 
.668 
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